Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Accounts Payables: 2011-2025

Historic Accounts Payables for Lifecore Biomedical (LFCR) over the last 15 years, with May 2025 value amounting to $8.2 million.

  • Lifecore Biomedical's Accounts Payables fell 49.68% to $8.2 million in Q2 2025 from the same period last year, while for May 2025 it was $8.2 million, marking a year-over-year decrease of 49.68%. This contributed to the annual value of $8.2 million for FY2025, which is 49.68% down from last year.
  • Per Lifecore Biomedical's latest filing, its Accounts Payables stood at $8.2 million for FY2025, which was down 49.68% from $16.3 million recorded in FY2024.
  • Lifecore Biomedical's Accounts Payables' 5-year high stood at $22.1 million during FY2023, with a 5-year trough of $8.2 million in FY2025.
  • In the last 3 years, Lifecore Biomedical's Accounts Payables had a median value of $16.3 million in 2024 and averaged $15.6 million.
  • In the last 5 years, Lifecore Biomedical's Accounts Payables crashed by 77.50% in 2021 and then soared by 70.61% in 2023.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Accounts Payables stood at $11.6 million in 2021, then grew by 11.44% to $13.0 million in 2022, then surged by 70.61% to $22.1 million in 2023, then declined by 26.08% to $16.3 million in 2024, then plummeted by 49.68% to $8.2 million in 2025.